Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.63 |
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276955 | 0.84 | ALDH1A1 (0.58) | KMT2AALDH1A1MEN1KDM4ELMNA | |
| SCHEMBL14145228 | 0.81 | F2 (0.54) | F2MAPK1NPC1RAB9AKMT2A | |
| SCHEMBL5429273 | 0.80 | F2 (0.58) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL5429275 | 0.80 | MAPK1 (0.65) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL8244239 | 0.79 | KDM4E (0.62) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL14627824 | 0.79 | MAPK1 (0.64) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL13754450 | 0.79 | SMN1; SMN2 (0.59) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL8629681 | 0.79 | F2 (0.57) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL6169349 | 0.78 | MAPK1 (0.59) | F2DAOGSK3BMAPK1HPGD | |
| SCHEMBL92875 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103130766-A | Piperine hydrazone or acylhydrazone or sulfonyl hydrazone derivative substances and application for preparing a botanical insecticide | UNIV NORTHWEST A&F | 2013-06-05 | — | — | CN | claimed |
| EP-3858342-A1 | ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-08-04 | — | — | EP | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020065119-A1 | ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2020-04-02 | — | — | WO | disclosed |
| EP-3309161-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-18 | — | — | EP | disclosed |
| US-20180258083-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. | 2018-09-13 | — | — | US | disclosed |
| US-10053462-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| EP-2968995-B1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2968995-B1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3309161-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| CN-102438990-A | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2012-05-02 | — | — | CN | disclosed |
| WO-2012035075-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012028644-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2408751-A1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053462-B2 | P2X7 modulators | P2RX1, P2RX5, P2RX7 | F2 2778/4885DAO 2555/4885GSK3B 1998/4885 |
| US-20180258083-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | F2 4041/4885DAO 2163/4885GSK3B 79/4885 |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | F2 1602/4885DAO 567/4885GSK3B 3724/4885 |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | F2 2871/4885DAO 252/4885GSK3B 2166/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | F2 2871/4885DAO 252/4885GSK3B 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.